CV Shariat_AKH - Vienna OMI

More documents

Recommendations

Info

• Canadian Institutes of Health Research 11/2010GENOMIC SIGNATURES IN BLADDER CANCERPrincipal Investigator: Black P.; Co-investigator: Shariat S.• CTSC Pilot award 6/2012METOBOLOMIC PROGNOSTICATION AND PREDICTION OF RESPONSE TO THERAPYIN NON-MUSCLEINVASIVE BLADDER CANCER (USD 45,000)Principal Investigator: Shariat S.P A T E N T S• Method to determine prognosis after therapy for prostate cancer 2002Inventors: Shahrokh Shariat, Kevin SlawinA method for prognosis of patients with prostate cancer, e.g., clinically localizedprostate cancer, is provided.EP1373899US20030054419WO02068960Patent record available from the European Patent OfficePatent record available from the US Patent OfficePatent record available from the World Intellectual Property Organization,Granted 2002-09-06• Methods to determine prognosis after therapy for bladder cancer 2003Inventors: Shahrokh Shariat, Kevin Slawin, Seth LernerA method to diagnose, stage and predict prognosis of bladder cancer patients is provided,e.g., using TGF-ß1, IL-6, IL-6sR, uPA, uPAR and IGFBP-3.US20030032074WO02099114Patent record available from the US Patent OfficePatent record available from the World Intellectual Property Organization,Granted 2003-06-19• Prognostic methods for patients with prostatic disease 2004Inventors: Shahrokh Shariat, Kevin Slawin, Michael Kattan, Peter ScardinoA method to diagnose, stage and predict prognosis of prostate cancer patients is provided.EP1540350US20030235816WO2004027432Patent record available from the European Patent OfficePatent record available from the US Patent OfficePatent record available from the World Intellectual Property Organization,Granted 2004-08-05• Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma 2010www.vienna-omi.at 28.08.2013
Inventor: Shahrokh ShariatThe present invention is an apparatus, system and method for detecting bladder cancerare provided that includes a substrate including one or more sFas binding agents and oneor more reagents that indicate the amount of sFas present in the sample.US07759077 Patent record available from the US Patent Office, Granted 2010-07-20P R O F E S S I O N A L R E S P O N S I B I L I T I E SEDITORIAL WORK• Editorial Board Member, European Urology 1/2008 – 12/2010Associate Editor1/2011 – present• Editorial Board Member, Immunotherapy 3/2008 – present• Contributor to Urology, Faculty of 1000 Medicine 5/2008 – 9/2010• Editorial Board Member, Debates on Bladder Cancer 9/2009 – present• Contributor, UpToDate 11/2009 – present• Editorial Board Member, Oncology Reports 12/2009 – present• Editorial Board Member, BJU Int 2/2010 – presentLeader of the Innovations Group• Section Editor for Urologic Oncology, Journal of Men’s Health 3/2010 – present• Editorial Board Member, World Journal of Clinical Oncology 4/2010 – present• Editorial Board Member, Journal of Molecular Biomarkers and Diagnosis 6/2010 – present• Editorial Board Member, Journal of Molecular Imaging & Dynamics 8/2010 – present• Editorial Board Member, World Journal of Clinical Urology 12/2010 – present• International Scientific Board, Archivos Españoles De Urologia 1/2011 – present• Consulting Editor, International Brazilian Journal of Urology 1/2011 – present• Editorial Board Member, ISRN Oncology 2/2011 – present• Editorial Board Member, Urology: Current Research (OMICS Publishing Group ) 3/2011 – present• Editorial Board Member, World Journal of Urology 7/2011 – presentAssociate Editor9/2011 – present• Editorial Board Member, Frontiers in Genitourinary Oncology 2/2012 –present• Co-editor of book on Prostate cancer –original scientific reports and case studies. 6/2012Edited by Spiess P.E.• Scientific board of Spectrum Urologie –offizielle Organ des Berufsverbands der 2/2013 -presentÖsterreichischen Urologen (BVU).• Bladder Cancer Advocacy Network’s scientific advisory board 3/2013 -present• Editorial Board Member, Advances in Therapy (ISSN: 0741-238X) 3/2013 -presentwww.advancesintherapy.com• Editorial Board Member, Journal of Tumor (ISSN 1819-6187) 3/2013 -present• Editorial Board Member, American Journal of Urology (ISSN 2162-9722) 5/2013 -presentMODERATED SESSIONS AT MEETINGS• Chair of Moderated Poster session: Urothelial tumours: Basic research I 2008www.vienna-omi.at 28.08.2013
Page 1 and 2: SHAHROKH F. SHARIAT, MDProfessor an
Page 3 and 4: E D U C A T I O N & M E D I C A L T
Page 5 and 6: • Glaxo SmithKline Scholar Award,
Page 7 and 8: May 29-June 3, 2010. J.Urol 183(4):
Page 9 and 10: • Leading Physician of the World
Page 11: Weill Cornell Medical Center, Princ
Page 15 and 16: • Chair of Sessions - The Inaugur
Page 17 and 18: • Guest Editor of special issue o
Page 19 and 20: • Visiting Professor, Division of
Page 21 and 22: Ablative therapy for small renal co
Page 23 and 24: Bladder cancer: opportunities for i
Page 25 and 26: 7. Merseburger AS, Herrmann TR, Sha
Page 27 and 28: 36. May M, Ficarra V, Shariat SF, Z
Page 29 and 30: Results from of a Large Multicenter
Page 31 and 32: trends and disparities in the use o
Page 33 and 34: 112. Abdollah F, Sun M, Thuret R, J
Page 35 and 36: 139. Fajkovic H, Cha EK, Jeldres C,
Page 37 and 38: RK, Margulis V, Shariat SF: Tissue-
Page 39 and 40: 21869907190. Abdollah F, Sun M, Jel
Page 41 and 42: Montorsi F, Karakiewicz PI: The imp
Page 43 and 44: Fradet Y, Shariat SF. Prognostic ri
Page 45 and 46: 271. Shariat SF, Lotan Y, Vickers A
Page 47 and 48: 298. Shariat SF, Kattan MW, Vickers
Page 49 and 50: 324. Capitanio U, Isbarn H, Shariat
Page 51 and 52: 349. Margulis V, Shariat SF, Matin
Page 53 and 54: 378. Karakiewicz PI, Bhojani N, Cap
Page 55 and 56: 410. Shariat SF, Lamb DJ, Iyengar R
Page 57 and 58: 442. Chun FK, Briganti A, Gallina A
Page 59 and 60: cystectomy for primary nontransitio
Page 61 and 62: Slawin KM. Salvage radiotherapy for
Page 63 and 64:
535. Shariat SF, Desai S, Song W, K
Page 65 and 66:
21. SunM., Abdollah F., Schmitges J
Page 67 and 68:
progression after radical prostatec
Page 69 and 70:
Y., Karakiewicz P.: Assessement of
Page 71 and 72:
50. Shariat S., Karakiewicz P., Fra
Page 73 and 74:
predictions in patients with adreno
Page 75 and 76:
Schoenberg, G. E. Amiel, S. P. Lern
Page 77 and 78:
113. Claudio Jeldres, Maxime Crepel
Page 79 and 80:
(volume 183 issue 4 Page e227)134.
Page 81 and 82:
156. Ramy Youssef, Shahrokh Shariat
Page 83 and 84:
Localized .Sunday, May 15, 2011 Ame
Page 85 and 86:
Health Conference. 2-5 October 2011
Page 87 and 88:
urothelial carcinoma. Poster #155.
Page 89 and 90:
supplementation on the prevention o
Page 91 and 92:
for metastatic renal cell carcinoma
Page 93 and 94:
muscle-invasive urothelial carcinom
Page 95 and 96:
Shahrokh Shariat Prediction of intr
Page 97 and 98:
Terrone; Derya Tilki; Daniel Vergho
Page 99 and 100:
P.I.: Drs. Shahrokh Shariat and Dou
show all

CV Shariat_AKH - Vienna OMI

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?